Screener
Recursion Pharmaceuticals, Inc. RXRX Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Loss from operations | (134,968) | (176,227) | (263,472) | (367,595) |
| Other income (loss), net | 3,962 | 4,330 | 10,359 | (6,947) |
| Loss before income tax benefit | (131,006) | (171,897) | (253,113) | (374,542) |
| Income tax benefit | 1 | — | 4,604 | 158 |
| Net loss | $(131,005) | $(171,897) | $(248,509) | $(374,384) |
| Per share data | ||||
| Net loss per share of Class A, B and Exchangeable common stock, basic and diluted | $(0.25) | $(0.41) | $(0.47) | $(0.91) |
| Weighted-average shares (Class A, B and Exchangeable) outstanding, basic and diluted | 532,460,085 | 417,361,147 | 530,890,753 | 410,268,199 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s business segments — net loss?
- Recursion Pharmaceuticals, Inc. (RXRX) reported business segments — net loss of -$131.01M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s business segments — net loss changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s business segments — net loss increased by 23.8% year-over-year, from -$171.9M to -$131.01M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s business segments — net loss?
- Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s business segments — net loss has grown at a 39.1% compound annual growth rate (CAGR), from -$239.48M to -$644.76M.
- What does business segments — net loss mean?
- This metric measures the bottom-line financial performance of the business segment after accounting for all revenues and operating expenses. A negative value indicates that the segment's costs, including research, development, and administrative overhead, exceed the revenue generated. It is a critical indicator of the segment's current profitability status and the burn rate required to sustain its specific operational objectives.
Ask your AI about Recursion Pharmaceuticals, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude